| # | Drug | Count |
|---|---|---|
| 0 | CAPECITABINE | 176 |
| 1 | TRASTUZUMAB | 170 |
| 2 | LETROZOLE | 166 |
| 3 | FULVESTRANT | 162 |
| 4 | LETROZOLE TABLETS | 137 |
| 5 | EVEROLIMUS | 135 |
| 6 | PACLITAXEL | 130 |
| 7 | EXEMESTANE | 126 |
| 8 | DOCETAXEL | 113 |
| 9 | DOCETAXEL ANHYDROUS | 113 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | INTERLEUKIN-10 | 3 | 0.0084 |
| 1 | VINORELBINE | 55 | 0.0079 |
| 2 | TALAZOPARIB | 11 | 0.0059 |
| 3 | EXEMESTANE | 126 | 0.0059 |
| 4 | ADO-TRASTUZUMAB EMTANSINE | 48 | 0.0057 |
| 5 | PAMIDRONATE DISODIUM | 18 | 0.0053 |
| 6 | TEBENTAFUSP | 3 | 0.0050 |
| 7 | FULVESTRANT | 162 | 0.0048 |
| 8 | EVEROLIMUS TABLETS | 74 | 0.0043 |
| 9 | LAPATINIB | 59 | 0.0038 |
| # | Drug class | Count |
|---|---|---|
| 0 | Aromatase Inhibitor [EPC] | 234 |
| 1 | Microtubule Inhibitor [EPC] | 216 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 214 |
| 3 | Kinase Inhibitor [EPC] | 208 |
| 4 | HER2/neu Receptor Antagonist [EPC] | 175 |
| 5 | Estrogen Receptor Antagonist [EPC] | 163 |
| 6 | Platinum-based Drug [EPC] | 143 |
| 7 | mTOR Inhibitor Immunosuppressant [EPC] | 136 |
| 8 | Corticosteroid [EPC] | 113 |
| 9 | Alkylating Drug [EPC] | 98 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 3 | 0.0050 |
| 1 | Estrogen Receptor Antagonist [EPC] | 163 | 0.0040 |
| 2 | Endoglycosidase [EPC] | 5 | 0.0027 |
| 3 | HER2/neu Receptor Antagonist [EPC] | 175 | 0.0023 |
| 4 | Aromatase Inhibitor [EPC] | 234 | 0.0021 |
| 5 | Lymphocyte Growth Factor [EPC] | 2 | 0.0016 |
| 6 | Microtubule Inhibitor [EPC] | 216 | 0.0013 |
| 7 | 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor [EPC] | 1 | 0.0012 |
| 8 | Nucleoside Metabolic Inhibitor [EPC] | 214 | 0.0008 |
| 9 | Somatostatin Analog [EPC] | 5 | 0.0007 |